Adam Feuerstein's take on the biotech sector's hits and misses during the week ended Dec. 10, 2010.
For these stocks trading for less than $5, a bankruptcy filing within two years is a probability.
EpiCept said it will offer 6.1 million shares of common stock at $1.10 per share.
Adam details his whereabouts on Sept. 9 and tackles readers' questions about Cyclacel, Epicept and a few more familiar names.
Genentech is advancing T-DM1, which uses ImmunoGen technology, into a phase III study as a second-line treatment for Her-2 positive metastatic breast cancer.
©1996-2017 TheStreet, Inc. All rights reserved.Action Alerts PLUS is a registered trademark of TheStreet, Inc.